Study says U.K. pipeline of advanced therapy research and products gaining strength

GSK gene therapy
A Cell and Gene Therapy Catapult study indicates continued strong growth of advanced therapy medicinal products in the U.K., backed by increased investment from commercial sponsors. (GSK)

A recent study released by the Cell and Gene Therapy Catapult indicates the continued strong growth of advanced therapy medicinal products in the U.K., backed by increased investment from commercial sponsors.

According to the study, 85 clinical trials and 875 preclinical research projects are currently ongoing in the cell or gene therapies arena, which is a 37% and 20% year-on-year gain, respectively. The study affirms the U.K. as a growing hub for the development and manufacturing of such therapies, the group said.

The organization points to two key developments last year: the opening of CGT Catapult’s cell and gene therapy manufacturing center in Stevenage; and the formation of a network of Advanced Therapies Treatment Centres that are designed to bolster the benefits and innovation for patients within the National Health System.

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

“We are building the world’s most complete advanced therapies ecosystem,” Keith Thompson, CGT Catapult’s chief executive, said in a statement. “As the number of clinical trials has accelerated, the U.K. has made a determined effort to scale up its research and manufacturing infrastructure to ensure this rich pipeline can continue to advance and grow.”

The government’s Industrial Strategy Challenge Fund has invested more than $89.3 million (£70 million) in the plan.

The number of cell and gene clinical trials in the U.K. that use gene modified therapies has grown from 47% in 2017 to 73%. Many of those trials have moved on to phase 3, the organization said.

Suggested Articles

U.S.-China biotech Brii Biosciences is pushing out into new territory with a new hire alongside a focus on a new R&D area.

John Ratliff’s position has changed three times this fall, but now, much like the falling leaves, he looks to have settled.

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.